Secretion of Fc-amidated peptide fusion proteins by Chinese hamster ovary cells by unknown
Carlson et al. BMC Biotechnology  (2015) 15:61 
DOI 10.1186/s12896-015-0173-5RESEARCH ARTICLE Open AccessSecretion of Fc-amidated peptide fusion
proteins by Chinese hamster ovary cells
Kristina R. Carlson1, Steven C. Pomerantz2, Jiali Li3, Omid Vafa2, Michael Naso2, William Strohl2,
Richard E. Mains1 and Betty A. Eipper1,4*Abstract
Background: The therapeutic use of α-amidated peptides (e.g. calcitonin, glucagon-like peptide) has increased
dramatically, but there are major impediments to wider use of such peptides. Larger peptides are expensive to
synthesize, and short plasma half-lives frequently limit the clinical circumstances in which the peptides would be
useful. Both problems are potentially solved by producing peptides as fusions with the Fc region of human
immunoglobulin.
Methods: Glucagon-like peptide 1 (GLP1), peptide YY (PYY) and neuromedin U (NMU) were expressed and purified
from stable CHO lines; since the α-amide group is essential for full biological potency of many peptides, Fc-fusion
peptides were expressed in CHO lines stably expressing the α-amidating enzyme, peptidylglycine α-amidating
monooxygenase (PAM: EC 1.14.17.3). Purified fusion proteins were analyzed intact and after HRV3C rhinovirus
protease cleavage, at a site in the linker separating the Fc region from the peptide, by mass spectrometry and
amide-specific immunoassays.
Results: The Fc fusions were expressed at 1–2.5 μg/mg cell protein and secreted at 5-20 % of cell content per hour,
in a peptide-specific manner. CHO cells express measurable endogenous PAM activity, amidating 25 % of Fc-PYY and
almost 90 % of Fc-GLP1. Expression of exogenous PAM increased the level of peptide amidation to 50 % of Fc-PYY
and 95 % of Fc-NMU. The Fc-GLP1 fusions were 10,000-fold less active than synthetic GLP1 in a cell-receptor cyclic
AMP-based assay, as expected since the amino terminal of GLP1 is essential for full biological activity. The Fc-PYY
fusions were 100-fold less active than PYY-NH2 but 10-fold more active than non-amidated PYY-Gly.
Conclusions: This type of approach can be used for the production of stabilized α-amidated peptides aimed at
clinical trials.
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The peptides used for intercellular communication are
generally short-lived, with half-lives of only a few mi-
nutes. The constant region of human immunoglobulin
(Fc, fragment crystallizable) is long-lived in the circula-
tion (2 weeks or more) and has been used to prolong the
half-lives of many proteins [1]. Many bioactive peptides
terminate with an essential C-terminal α-amide [2, 3]. C-
terminal α-amidation requires the α-hydroxylation of a* Correspondence: eipper@uchc.edu
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creativecommons.org/publicdomain/zero/1.0/peptidylglycine precursor by peptidylglycine α-hydroxylating
monooxygenase (PHM) and subsequent cleavage of the
α-hydroxylated intermediate by peptidyl-α-hydroxyglycine
α-amidating lyase (PAL) to produce the amidated product
and glyoxylate. A bifunctional type 1 integral membrane
protein, peptidylglycine α-amidating monooxygenase (PAM),
is the only enzyme known to catalyze this reaction [3, 4].
We wanted to determine whether Fc-amidated peptide
fusion proteins could be produced from Fc-peptidylglycine
precursors and secreted efficiently and whether the prod-
ucts would be biologically active. Chinese hamster ovary
(CHO) cells are widely used for the production of recom-
binant antibodies and up to 70 % of all biopharmaceuticals
[5]. CHO cells were also used to produce PHM and PALrticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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encodes PAM splice variants similar to those found in
rat and human (e.g. Cricetulus griseus, XP_003505818.1;
Homo sapiens, NP_000910; Rattus norvegicus, NP_037132).
Endogenous PAM activity is detectable in CHO cells, but
levels are substantially below those found in professional
secretory cells such as pituitary endocrine cells and atrial
myocytes [8]. Consistent with the expression of PAM in
CHO cells, many CHO cell monoclonal antibody prepara-
tions consist of mixtures of α-amidated and non-amidated
product [5, 9–11]. We compared the ability of wildtype
CHO cells and CHO cells expressing exogenous membrane
or soluble PAM to secrete Fc-amidated peptide fusion
proteins.
The growth hormone signal sequence was placed be-
fore the sequence of human Fc and a cleavable linker
was placed between the C-terminus of Fc and the pepti-
dylglycine substrate to facilitate product analysis. Three
peptidylglycine substrates were selected for study. Pep-
tide YY (PYY), which plays an important role in the
response of the endocrine pancreas to oral glucose, termi-
nates with -Tyr-NH2; amidation of its C-terminus is es-
sential for bioactivity [12]. Neuromedin U (NMU), which
is expressed in the gastrointestinal tract and brain and
plays a major role in regulating energy balance, terminates
with -Asn-NH2; amidation of its C-terminus is also essen-
tial for full bioactivity [13]. Glucagon-like peptide
1(GLP1), which stimulates pancreatic β cells to proliferate
and release insulin in response to oral glucose, terminates
with -Arg-NH2; its C-terminus is not essential for bio-
activity [14, 15], but the high Km values for –Arg-Gly pep-
tides suggested that GLP1-Gly would be a good test case
[16]. By placing the peptidylglycine substrate at the C-
terminus of the Fc-fusion protein, any need for endo- or
exoproteases in the biosynthetic pathway was eliminated.
Results
Design of vectors encoding Fc-amidated peptide
precursors
The active site of PHM requires the presence of a C-
terminal Gly; for most neuroendocrine peptide pre-
cursors, cleavage by an endoprotease followed by an
exoprotease is required to generate the peptidylglycine
substrate. To focus on the requirements for peptide ami-
dation in the cellular environment, we appended the
peptidylglycine substrates to the C-terminus of human
Fc (Fig. 1a). The human growth hormone signal was
used to ensure efficient protein entry into the secretory
pathway. Use of two different linker peptides [(AP)10 or
(GGS)6GG], was explored and a proteolytic cleavage site
was inserted after the linker region so that the peptide
product could easily be separated from the Fc-region, fa-
cilitating analysis of its amidation. Although PHM can
accommodate any amino acid in the penultimate position,hydrophobic residues facilitate substrate binding [17].
To evaluate the effect of the penultimate amino acid on
extent of amidation (the amidated residue is noted in
parenthesis), we constructed vectors encoding GLP1-Gly
(−Arg-NH2), NMU-Gly (−Asn-NH2) and PYY-Gly
(−Tyr-NH2) (Fig. 1b).
The ability of GLP1-Gly and PYY-Gly to interact with
PAM was assessed using synthetic peptides and purified
soluble recombinant PAM (PAM820s). PAM activity was
quantified using [125I]-Acetyl-Tyr-Val-Gly. The ability of
synthetic GLP1-Gly and synthetic PYY-Gly to inhibit this
reaction was assessed; data were plotted in Eadie-
Hofstee format (Fig. 1c). While PYY-Gly had a Ki in the
low μM range, the Ki of GLP1-Gly was about 50-fold
higher. Predicted Vmax values were also much higher for
GLP1-Gly than for PYY-Gly, so that their catalytic effi-
ciencies (kcat/Ki) were similar (Fig. 1c and d).
Transient expression of the Fc-peptidylglycine fusion
proteins was used to verify secretion of Fc proteins of
the expected mass; secreted fusion proteins were detected
using antibody to human Fc (Fig. 1e). Spent medium con-
tained only the intact fusion proteins; there was no indica-
tion of degradation. The choice of linker had no effect on
secretion of product, but the slightly greater mass of the
(AP)10 linker [(AP)10, 1700 daltons; (GGS)6GG, 1139 dal-
tons] was apparent.
CHO lines used to express Fc-peptidylglycine fusion
proteins
Earlier experiments documented the presence of PHM
activity in CHO cell lysates [6] and the secretion of ami-
dated peptides by CHO cells expressing exogenous pep-
tide precursors [18]. However, the properties of CHO
cell PAM have not been reported. Analysis of the Crice-
tulus griseus genome revealed the existence of tran-
scripts corresponding to the major PAM splice variants
detected in rat and human (Fig. 2a). While Cricetulus
griseus isoforms 1, 2 and 4 would be integral membrane
proteins, isoforms 3 and 5 would be soluble proteins.
Isoforms 1 and 2 are products of alternative splicing at
exon/intron junctions preceding and immediately fol-
lowing the transmembrane domain and differ in length
by only three amino acids.
Endogenous PHM activity was detected in both crude
particulate and soluble fractions prepared from CHO
cells (Fig. 2b). PHM specific activity in the particulate
fraction was 2.5 times higher than in the soluble frac-
tion; 70 ± 5 % of the PHM activity in CHO cell lysates
was particulate. The specific activity of PHM in CHO
cell lysates was below levels observed in corticotrope
tumor cells [19], making it impossible to characterize in
crude extracts using existing antisera.
Immunoprecipitation was used to enrich PAM found
in the TX-100 solubilized particulate fractions prepared
Fig. 1 Design of vectors encoding Fc-peptidylglycine precursors. a Key features of the Fc-peptidylglycine precursors are illustrated. b The amino
acid sequences of human GLP1-Gly, PYY-Gly and NMU-Gly are shown (http://www.bachem.com/research-products/). c Eadie-Hofstee plots
illustrating the effects of synthetic PYY-Gly and GLP1-Gly on conversion of [125I]-Acetyl-Tyr-Val-Gly into [125I]-Acetyl-Try-Val-NH2 by purified PAM
820 s (0.085 ng/40 μl ≈ 1 fmol enzyme/tube). d Calculated kinetic parameters for PYY-Gly and GLP1-Gly. e pEAK Rapid cells were transiently
transfected with vectors encoding Fc-GS-GLP1 (calculated mass discounting oligosaccharides; 31,720), Fc-AP-GLP1 (mass; 32,020), Fc-GS-PYY (mass;
32,730) and Fc-AP-PYY (mass; 33,090); control non-transfected cells (non) were analyzed at the same time. Aliquots of spent medium (20 μl) were
fractionated by SDS-PAGE and visualized using antibody to human Fc; 18 ng human IgG (hIgG) was analyzed at the same time
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specific to the C-terminus of PAM, which is identical in
mouse and Chinese hamster, was used to enrich CHO cell
PAM. After separation by SDS-PAGE, antibody specific
for the PHM region was used to determine the molecular
weights of any cross-reactive proteins. For comparison, a
PAM1 CHO cell lysate was immunoprecipitated at the
same time. The minor 113 ± 4 kDa CHO cell protein rec-
ognized by the PHM antibody was also visualized by an
antibody specific for exon 16 (not shown) and has the
properties expected of isoforms 1 and 2 (PAM1). The
closely spaced doublet of bands at 97 ± 3 kDa and 92 ±
2 kDa could represent Chinese hamster isoforms 3, 4
(PAM2) and 5; the lower band in the doublet is recognized
by the exon 16 antibody. The 77 ± 2 kDa PAM protein is
smaller than any of the characterized splice variants and
may represent a cleavage product.We next compared the level of PHM activity in wild-
type CHO cells to the level present in CHO cells stably
expressing PAM1 or PAM820s (Fig. 2d). Based on PHM
specific activity, expression of PAM1 and PAM820s in
the CHO lines used for expression of Fc-peptidylglycine
fusion proteins was 10- and 100-fold higher, respectively,
than endogenous PHM levels. In each line, PAL specific
activity was approximately 10-fold higher than PHM
specific activity, as expected [20].
Characterization of Fc-peptidylglycine fusion proteins
expressed by wildtype and PAM-expressing CHO cells
We first examined the ability of stably transfected CHO
cell lines to produce and secrete the three Fc-peptide fu-
sion proteins; the amount of product recovered in spent
medium was compared to the amount present in cell ex-
tracts (Fig. 3a-c). Fc content (μg Fc/mg protein) and
Fig. 2 Characterization of endogenous CHO cell PAM. a Five isoforms of Cricetulus griseus PAM are included in the primary RefSeq assembly of
the Chinese hamster genome; these isoforms closely resemble those observed in rat, mouse and human: XP_003505817.1, isoform 1; ERE82825.1,
isoform 2; XP_003505819.1, isoform 3; XP_003505820.1, isoform 4; XP_003505821.1, isoform 5. b The specific activity of endogenous PHM in the
soluble (TM) and solubilized (TMT) crude particulate fractions is indicated. c The solubilized particulate fraction from two separate preparations of
wildtype CHO cells (224 μg protein) and from CHO cells stably expressing PAM1 (20 μg protein) were immunoprecipitated using an affinity-
purified antibody to the C-terminus of PAM, eluted and fractionated by SDS-PAGE, transferred to PVDF membranes and visualized using affinity-
purified antibody to the PHM domain (JH1761); molecular weights of marker proteins analyzed along with PAM1 are indicated. A lighter exposure
is shown for the other Wt sample so that the doublet of 92 and 97 kDa bands is visible. Apparent molecular weights calculated from three separate
analyses are shown ± Std Dev. d PHM and PAL assays were performed on lysates prepared from wildtype CHO cells and from CHO cells stably
expressing rat PAM1 or rat PAM 820 s; lysates were prepared in 1 % TX-100
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cell line. For Fc-GLP1 and Fc-NMU, fusion proteins con-
taining both the AP and GS linkers were examined; no
linker-related differences were apparent. For Fc-PYY,
only the fusion protein with a GS linker was examined.
Cell content of Fc was similar (1.3-2.6 μg Fc/mg cell pro-
tein) for all of the lines examined (Fig. 3d). The secretion
rates varied from 5 % - 20 % of cell content per hour
(Fig. 3e).
The same Fc-peptidylglycine fusion proteins were also
expressed in CHO lines expressing exogenous PAM. Fc
content and secretion rate were quantified for the PAM-
expressing CHO cell lines in the same manner as for
wildtype CHO cell lines (Fig. 4). Fc-GLP1 with the AP
linker and Fc-PYY with GS linker were expressed in
PAM1 CHO cells. Fc-NMU with both the AP and GS
linkers was expressed in PAM820s CHO cells. Western
blot analyses are shown (Fig. 4a-c), along with quantifi-
cation of Fc content (Fig. 4d) and secretion rate (Fig. 4e).
As for wildtype CHO lines, cell content of Fc ranged
from 2–4 μg Fc/mg cell protein for all of the lines andFc secretion rates were all in the range of 12-22 % of cell
content per hour.
Purification of secreted Fc-fusion proteins and evaluation
of amidation status
Monolayer cultures of stably transfected CHO lines were
fed with complete serum-free medium every other day
for a week; after concentration, spent media were applied
to Protein A cartridges and bound Fc-fusion proteins were
eluted with low pH buffer. SDS-PAGE analysis of the elu-
ates, along with recombinant Fc, established their purity
(Fig. 5a). Yields ranged from 1 to 5 mg purified Fc-fusion
protein per liter of spent medium. Intact mass analysis of
each product revealed the presence of a disulfide bonded
dimer with a biantennary, core-fucosylated glycan. The
observed glycosylation heterogeneity illustrated for the Fc-
AP-GLP1 construct (Fig. 5b) was more diverse than is typ-
ically encountered in manufacturing CHO cell lines used
for biotherapeutic (mAb) production, as exemplified by
the Fc standard (Fig. 5c). The presence of some hybrid
glycoforms would indicate that a low percentage of the
Fig. 3 Characterization of Fc-fusion protein expression and secretion in wildtype CHO lines. Samples of cell extract (CE) and spent medium (16 h
collection) prepared from CHO lines expressing Fc-AP-GLP1 (a) [15 μg (7 %) of CE; 0.9 % of spent medium], Fc-GS-PYY (b) [10 μg (8.5 %) of CE;
1.3 % of spent medium) and Fc-AP-NMU (c) [10 μg (5.3 %) of CE; 1.3 % of spent medium) were fractionated by SDS-PAGE; samples and a human
IgG standard were visualized using antibody to human Fc. d Using GeneTools, data from several similar analyses (n = 3–4) were quantified to
determine μg Fc/mg cell protein. e The secretion rate for Fc was calculated for several experiments by quantifying the amount of Fc recovered from
the cell extract (CE) and from the medium using GeneTools; for each cell line, secretion rate was expressed as % cell content secreted per hour
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full transit of the Golgi) or there was competition for
substrate which interfered with glycosyltransferases.
Intact mass analysis was not precise enough to deter-
mine the degree of C-terminal amidation. Therefore, ex-
tent of amidation was quantified by analysis of the
HRV3C rhinovirus protease cleavage products (Fig. 6a).
Peptidylglycine precursors differ from their amidated
products by a mass of +58; amidated peptides differ
from the corresponding peptide with a free COOH-
terminus by a mass of −1 and a charge change (+1) at
neutral pH. Intact mass analysis of the cleaved proteins
allowed reliable identification of amidated product and
glycine-extended precursor (Fig. 6b). Product lacking the
COOH-terminal Gly, with a free COOH-terminus was
not identified. Some off-target cleavage by rhinovirus
protease was observed; instead of the expected cleavage
between Q and G248 (LEVLFQ/GP), cleavage occasion-
ally occurred before F246 or Q247. Each purified product
was analyzed in triplicate. For each substrate, the per-
cent amidated was calculated by summing amidated plus
glycine-extended peptide to determine the total amount
of peptide recovered, and assumes there is no differencein HRV3C specificity or cleavage rate between the two
substrates.
Fc-GLP1 was almost 90 % amidated, even when ex-
pressed in wildtype CHO cells having only endogenous
levels of PAM (Fig. 6c). No difference in extent of Fc-
GLP1 amidation was observed in CHO cells expressing
PAM1. In contrast, less than 30 % of the Fc-PYY pro-
duced by wildtype CHO cells was amidated; expression
of PAM1 increased the extent of PYY amidation by
about a factor of two (Fig. 6c). Approximately 71 % of
the Fc-NMU produced by wildtype CHO cells was ami-
dated; Fc-AP-NMU and Fc-GS-NMU did not differ in
their extent of amidation. Fc-NMU produced by CHO
cells expressing soluble PAM (PAM820s) was over 90 %
amidated, a significant increase over the extent of ami-
dation observed in wildtype CHO cells.
Assessment of biological activity
The peptidylglycine substrates tested each yield ami-
dated peptides that interact with specific GPCRs. We
therefore used cell-based receptor assays to test the bio-
logical activity of two of the purified secreted Fc-fusion
proteins. The concentration of each Fc-fusion protein
Fig. 4 Characterization of Fc-fusion protein expression in CHO lines expressing PAM. Fc-AP-GLP1 (a) and Fc-GS-PYY (b) were expressed in PAM1
CHO cells; Fc-AP-NMU (c) was expressed in PAM820s CHO cells. Aliquots of cell extract (a, 5 %; b, 3 %; c, 6 % of total cell extract) and spent
medium (a, 0.7 %; b, 1.3 %; c, 2.3 % of total medium volume) were prepared as described for Fig. 3. d Using GeneTools, data from several similar
analyses were quantified to determine μg Fc/mg cell protein (d) and Fc secretion rate (e)
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erated using purified human Fc analyzed on the same
Western blot.
The bioassay for GLP1 used HEK cells expressing the
GLP-1R; synthetic GLP1-Ser8 was used as the standard
and had an EC50 of 2.8 pM (Fig. 7a). The NH2-terminus
of GLP1 plays an essential role in its interaction with re-
ceptor and the addition of the GP dipeptide to the NH2-
terminus of synthetic GLP1 increased its EC50 to 25.8
pM (Fig. 7a). The corresponding glycine-extended peptide
had a similar EC50, as expected for a ligand/receptor
interaction that is known not to require the COOH-
terminus of the ligand [14, 15]. Although the intact Fc-
GLP1 fusion proteins tested yielded dose response curves
that were parallel to those of GLP1, they were at least
10,000-fold less potent than GLP1; their EC50 values were
in the 100 nM range (Fig. 7b).
The bioassay for PYY used CHO cells expressing the
NPY-2R; synthetic PYY(3–36)NH2 was used as the
standard and had an IC50 of 1.2 nM (Fig. 8). Synthetic
peptides corresponding to full-length PYY with the GPdipeptide left by rhinovirus protease cleavage of the
Fc-PYY substrate were used to evaluate the effect of
COOH-terminal amidation. GP-PYY-NH2 was slightly
more potent than PYY(3–36)NH2 while GP-PYY-Gly was
1000-fold less potent (Fig. 8). The Fc-PYY products exam-
ined yielded dose response curves that were parallel to
those of PYY(3–36)NH2 and GP-PYY-NH2. Although
their IC50 values were at least 100-fold higher than the
synthetic peptide, the Fc-PYY products were 10-fold more
potent than GP-PYY-Gly.
Discussion
CHO cells have served as excellent mammalian cell fac-
tories for making proteins that are difficult or impossible
to create in bacterial and yeast systems [5]; the α-
amidating enzyme, PAM, falls into this category and has
been successfully expressed in CHO cells [21–24]. Thus,
to produce large, α-amidated proteins for therapeutic or
investigational purposes, CHO cells were selected. The
plasma half-life of many peptides has been increased
several orders of magnitude by fusion with the Fc region
Fig. 5 Purification and mass spectroscopic analysis of Fc-fusion proteins. a After concentration using a Vivaflow flip flow filtration system and a
Centricon, secreted Fc-fusion proteins were purified by binding to HiTrap Protein A cartridges; bound protein was eluted by application of low
pH buffer and aliquots (E1-E4) were subjected to SDS-PAGE; purified Fc was analyzed at the same time. Comparison of glycan heterogeneity by
intact mass analysis of Fc-AP-GLP1 (b) and Fc from manufacturing cell line (c). Peak labels are shorthand notation for glycosylation state. All
molecules exhibited two bi-antennary core fucosylated glycans (BiF/BiF) with an additional Gn (n = 1-4) galactose and Sn (=1–2) sialic acid
(N-acetylneuraminic acid) moieties distributed between the two glycans
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fusion a desirable starting point to make long-lived pro-
teins terminating with the α-amidated peptide of interest.
Although the specific activity of endogenous CHO cell
PAM is low compared to endocrine cells or atrial myo-
cytes [25], it is clearly capable of α-amidating exogenous
proteins. CHO cells expressing monoclonal antibodies
that terminate with a C-terminal Gly residue are often
partially α-amidated [5, 9]. The ability of endogenous
CHO cell PAM to α-amidate a significant amount of
each Fc-peptidylglycine precursor is consistent with the
properties of PAM established using test tube assays and
the levels of enzyme and substrate expressed. When
assayed with substrate levels well below the Km of the
enzyme (0.5 vs. 9.2 μM; Fig. 1), non-transfected CHO
cells had a specific activity of 0.1 nmol/mg protein/h
(Fig. 2); based on Michaelis-Menten kinetics and allowing
for the molecular weight of the fusion protein, thiscorresponds to a maximal amidation rate of 45 μg Fc-
peptide/mg protein/h. Since the cell lines studied here
contained only 1–3 μg Fc-peptide/mg protein and se-
creted only 5 to 20 % of their cell content per h (Fig. 3),
they would be expected to α-amidate a significant fraction
of the secreted Fc-peptide. Cell lines producing signifi-
cantly more Fc-peptide may need exogenous PAM and in-
creased storage capacity to produce more extensively
amidated product.
Comparison of cell-based and test tube assays suggests
that PAM is operating at close to Vmax in cells – its af-
finity for the Fc-peptidylglycine substrate is not a major
factor. GLP1-Gly, with a penultimate Arg residue, was
more extensively amidated than PYY, with a penultimate
Tyr residue (Fig. 6c). By comparison, in test tube assays,
peptides ending in –Aromatic-Gly are better substrates
than peptides ending in –Charged-Gly [16]. The more
rapid secretion of Fc-PYY than Fc-GLP1 (Fig. 3e) may
Fig. 6 Reversed-phase HPLC-MS analysis of HRV3C cleavage products. a Total ion chromatogram (TIC); b single-charge deconvoluted mass
spectrum (MaxEnt3) from the m/z data under the peptide peak. c Purified Fc-fusion proteins were cleaved with HRV3C protease and subjected to
mass spectroscopic analysis as described in Methods. Each sample was analyzed in triplicate; standard errors are shown
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for this difference is not apparent. The very high con-
centration of protein in the lumen of the secretory path-
way (over 100 mg protein/ml) is difficult to mimic in
test tube assays [26, 27].
Both the cellular machinery and substrate will need to
be optimized in order to achieve the maximal yield of ex-
tensively α-amidated product. Clearly the rate of secretion
of the Fc-fusion peptide (Fig. 3) has a role, since the Fc-
peptides secreted slowly (GLP1 and NMU: 5-9 % of cell
content/h; Fig. 3) were highly amidated without the need
for additional PAM (Fig. 6c). By contrast, the cells which
secreted the fusion peptide rapidly (PYY; Fig. 3) showed
less extensive α-amidation of the peptide (25 %; Fig. 6c)
and the extent of amidation was improved by expression
of exogenous PAM (50 %; Fig. 6c). Fc-PYY provides a bet-
ter test case for assessing modifications aimed at increas-
ing the extent of α-amidation than Fc-GLP1.
Conclusions
The ultimate goal of this work is creation of long-lived
peptides for therapeutic or investigational uses. Thepeptides chosen for this initial study were selected to an-
swer specific questions about the methodology and the
ability of PAM to handle different substrates. The limited
ability of Fc-PYY-NH2 to activate the NPY-2R may reflect
the role of the N-terminal region of PYY in its interaction
with receptor [28] or interference by the Fc-region with
access of PYY-NH2 to its receptor. A different carrier pro-
tein might better confer stability to the fusion protein
without compromising receptor accessibility. The proper-
ties of the carrier protein may also determine the speed
with which it traverse the secretory pathway and the time
over which it is exposed to PAM. The properties of PAM
are unlikely to limit the choice of carrier protein. Fusion
protein stability will need to be assessed; the ability of
purified Fc-PYY to activate the NPY-2R may reflect cleav-
age during the incubation with cells. It is not currently
feasible to attempt to recover the peptide after the bio-
assay, and any cleaved peptide that was endocytosed by
the reporter cells would also be missed. Whether using
their endogenous enzyme or exogenous PAM, CHO cells
can efficiently amidate large proteins that terminate with a
Gly residue.
Fig. 7 Bioassay of purified Fc-GLP1 fusion proteins. HEK cells expressing the GLP-1R were used to assess the ability of Fc-GLP1 fusion proteins
purified from the spent medium of different CHO cell lines to stimulate cAMP production. a The activity of GLP1, GP-GLP1-NH2 and GP-GLP1was
compared; as expected, amidation did not affect bioactivity while appending the GP dipeptide to its amino-terminus reduced the potency of
GLP1-NH2. b The activity of GLP1 was compared to that of Fc-AP-GLP1 fusion proteins purified from the spent media of WT CHO cells, CHO cells
expressing PAM1 and WT CHO cells treated with 10 μM bathocuproine disulfonate to inhibit endogenous PHM throughout the entire collection
period. Parallel dose–response curves were observed for all of the peptides and proteins tested; Fc-GLP1 was at least 10,000-fold less active than
GLP1. The y-axis shows the TR-FRET signal at 665 nm; the signal obtained by cells in the absence of any added peptide is indicated
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Expression vector design
Two linker peptides were used: AP, (Ala-Pro)10; GS,
(Gly-Gly-Ser)6-Gly-Gly. Expression vectors encoding Fc-
AP-GLP1-Gly, Fc-GS-GLP1-Gly, Fc-AP-NMU-Gly, Fc-Fig. 8 Bioassay of purified Fc-PYY fusion proteins. CHO cells expressing the
purified from the spent medium of different CHO lines to inhibit forskolin-s
decreasing cAMP production. Synthetic PYY(3–36)NH2 was more potent than
potent than the corresponding amidated peptide. Although the Fc-PYY fusio
synthetic GP-PYY-NH2, it was 10-fold more active than synthetic GP-PYY-Gly. P
proteins testedGS-NMU-Gly, Fc-AP-PYY-Gly and Fc-GS-PYY-Gly were
synthesized at Genewiz, Inc. (South Plainfield, NJ) and
cloned into an expression vector with a blasticidin se-
lectable marker. The GH signal sequence preceded hu-
man IgG1(CPPCPA—LSLSPG). A 20 residue AP linkerNPY-2R were used to assess the ability of Fc-PYY fusion proteins
timulated cAMP production; PYY binding to NPY-2R activates Gαi,
synthetic GP-PYY-NH2; synthetic GP-PYY-Gly was at least 10,000-fold less
n protein produced by PAM1 cells was about 200-fold less active than
arallel dose–response curves were observed for all of the peptides and
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GP] was appended to residue 475 of human IgG1
(AAA02914.1); cleavage at the HRV3C human rhinovirus
protease site adds a Gly-Pro to the N-terminus of the
product peptide.
Generation of cell lines
In addition to wildtype CHO DG44 cells, we selected
CHO lines expressing PAM1 and PAM820s encoded by a
pCis vector, using selection in αMEM lacking nucleotides
and nucleosides [29]. For cells transfected with vectors
conferring blasticidin resistance, growth medium was a 1:1
mixture of Dulbecco’s Modified Eagle’s Medium:Ham’s
F-12 [Lonza, Allendale, NJ] containing 25 mM Hepes,
50 IU/ml Penicillin, 50 μg/ml streptomycin [Cellgro,
Manassas, VA], 10 % fetal bovine serum [Hyclone, Waltham,
MA] and 3 μg/ml blasticidin [InvivoGen, San Diego,
California]. For cells transfected with pCis vectors, growth
medium was αMEM [Cellgro, Manassas, VA] containing
25 mM Hepes, 50 IU/ml Penicillin, 50 μg/ml strepto-
mycin, 10 % dialyzed fetal bovine serum and 2 mM L-
glutamine [Cellgro]. Doubly transfected cells were
maintained in the pCis selection medium with 3 μg/ml
blasticidin. Cells were passaged using trypsin-EDTA
[Cellgro].
CHO DG44 cells grown to 50 % confluence in T75
flasks [BD Falcon, Franklin Lakes, New Jersey] were rinsed
with 20 ml of serum free medium for 30 min prior to
transfection. Cells were transfected using 30 μg plasmid
DNA, 60 μl Lipofectamine incubated in 200 μl Opti-
MEM [Invitrogen, San Diego, California] and diluted into
5 ml Opti-MEM before application onto the cells; trans-
fection solution was removed after 7 h and cells were fed
with the appropriate growth medium containing 3 μg/ml
blasticidin. To screen for Fc-peptide secretion, single col-
onies in a 96-well plate [Corning, Manassas, VA] were fed
with 80 μl CSFM; spent medium was harvested the next
morning, and 20 μl was fractionated by SDS-PAGE on a
10 lane, 4-15 % Tris–HCl Precast gel [Bio Rad, Hercules,
CA]. Secreted product was visualized using rabbit anti-
human Fc [309-001-008; Jackson Immunoresearch, West
Grove, PA]. Selected single colonies were trypsinized and
cells were transferred into one well of a 12-well plate
[Corning, Manassas, VA]. After the cells had grown for
several days, they were trypsinized so that one aliquot
could be frozen and another aliquot subcloned again using
a 96-well plate. Subcloning was repeated until all of the
single colonies tested were positive for Fc secretion and a
colony was selected for use.
Analysis of Fc-peptide fusion protein and PAM expression
and secretion
Cells were grown to confluence in 6- or 12-well dishes.
Secretion rates for Fc-peptide fusion proteins and forPAM were determined by incubating cells in complete
serum free medium (CSFM) containing 25 mM Hepes,
50 IU/ml Penicillin, and Insulin-Transferrin-Selenium
[Invitrogen, San Diego, California] [3, 4]. Spent medium
was collected, centrifuged to remove any cell debris and
stored frozen after addition of protease inhibitors [30].
For assessment of PHM and PAL activity in cell lysates,
cells were extracted into ice cold 20 mM TES, 10 mM
mannitol, titrated to pH 7.4 with NaOH (TM), or with
added 1 % TX-100 (TMT) (SurfActs, Pierce, Waltham,
MA) containing PMSF and protease inhibitors [30]; ex-
tracts were frozen and thawed 3 times, centrifuged at
14,000 x g for 15 min, and supernatants were stored in
aliquots at -80C. For evaluation of Fc-peptide fusion pro-
tein secretion, cells were extracted by heating for 5 min
at 95 °C in SDS lysis buffer.
Cell lysate protein concentrations were determined
using the BCA Assay with bovine serum albumin as the
standard [Pierce, Waltham, MA]. Samples for SDS-
PAGE were diluted into 1X or 5X Laemmli sample buf-
fer, heated for 5 min at 95 °C and loaded onto 4-15 %
Tris–HCl 12 + 2 well Criterion Precast Gels [Thermo
Scientific, Waltham, MA]. A high molecular weight Pre-
cision Plus standard [Bio-Rad, Hercules, CA] was ana-
lyzed each time. Electrophoresis was carried out for
90 min at 150 V; proteins were transferred onto Immo-
bilon PVDF membranes for 120 min at 300 mAmp.
Membranes were blocked by incubation in 5 % fat-free
powdered milk in 50 mM Tris·HCl, 150 mM NaCl,
pH 7.5 containing 0.1 % Tween-20 (TTBS) for 1 h at RT
[6, 7]. Primary antibodies were diluted into TTBS. Incu-
bation with primary antibody was carried out at 4° C
overnight. Membranes were washed 3X in TTBS and
HRP-tagged secondary antibody diluted into TTBS was
then added. Blots were incubated in secondary antibody
for 2 h at RT and then washed 3X in TTBS and 1X in
TBS. SuperSignal West Pico Chemiluminescent Sub-
strate [Pierce, Rockford, IL] was added for 5 min at RT,
and signals were visualized using a GeneGnome digital
imaging system [Syngene, Frederick, MD]. GeneTools
software [Syngene, Frederick, MD] was used for quanti-
fication; exposure times were selected to avoid satur-
ation. A rectangle of equal size was used to identify each
band; the automatic background correction was utilized.
The signal for each sample was converted into pmol IgG
or Fc using a conversion factor calculated from the hu-
man IgG or Fc standard analyzed on the same blot.
Purified human IgG [I4506, Sigma, St. Louis, MO] was
dissolved in PBS; based on the A280 of a 10-fold dilution
of this stock, its concentration was 7.3 mg/ml (extinc-
tion coefficient at 280 nm for human IgG 1.40; Thermo
Scientific TechTip #6). Further dilutions were made so
that 54 ng and 18 ng of hIgG was loaded onto a gel;
1 ng = 20 fmol monomer. Purified recombinant human
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munoglobulin was also used as a standard for SDS-
PAGE; based on the A280 of a 10-fold dilution of this
stock, its concentration was 30.6 mg/ml (extinction coef-
ficient at 280 nm for human Fc, 1.334). Further dilutions
were made so that 25 ng, 10 ng, and 5 ng of human Fc
was loaded onto a gel; 1 ng = 28.6 fmol monomer.
Enzyme assays
Samples of spent media or cell extracts were diluted into
PHM diluent (20 mM NaTES, pH7.4, 10 mM mannitol,
1 % TX-100 [SurfActs, Pierce, Rockford, IL], 1.0 mg/ml bo-
vine serum albumin). The 40 μl reaction mixture contained
a trace amount of [125I]-Ac-Tyr-Val-Gly, 2 μM CuSO4,
0.5 mM ascorbate, catalase, and 0.5 μM AcTyrValGly di-
luted into 150 mM NaMES, pH 5.5 [6]. Samples were
assayed in duplicate at two dilutions and data were aver-
aged. For PAL assays, each tube contained a trace amount
of [125I]-Ac-Tyr-Val-α-hydroxylglycine, 0.5 μM Ac-Tyr-
Val-α-hydroxylglycine, 0.05 % NP-40 and 1 mM CdCl2 di-
luted into 150 mM NaMES, pH 5.5 [7]. Samples were
assayed in duplicate and data were averaged; assays typic-
ally contained 0.02 μg to 1.4 μg cell protein.
The ability of synthetic peptidylglycine peptides to in-
hibit the amidation of Ac-Tyr-Val-Gly was assessed by add-
ing increasing concentrations of competitor to the assay
mix. The PYY-Gly peptide (MW 4522) and the GLP1-Gly
peptide (MW 3509) each included an N-terminal Gly-
Pro dipeptide, to mimic the product expected from
rhinovirus protease cleavage. Peptides were synthesized
by New England Peptide (Gardner, MA) and were >99 %
pure based on RP-HPLC/MS analyses performed in-
house.
Analysis of endogenous CHO cell PAM
Wildtype CHO cells were rinsed with CSFM and cell
pellets were extracted by freeze/thaw cycles in 20 mM
NaTES, 10 mM mannitol, pH 7.4 (TM); lysates were
then centrifuged to separate the soluble fraction from
the crude particulate fraction. Proteins in the crude par-
ticulate fraction were solubilized in TMT. Endogenous
PAM recovered in the solubilized particulate fraction
was immunoprecipitated using affinity-purified antibody
to the C-terminus of PAM (0.5 μg C-STOP antibody for
90 to 230 μg CHO cell protein) [31]. PAM/antibody
complexes were bound to Protein A Sepharose beads
and eluted by incubation in Laemmli sample buffer at
95 °C. Eluates were fractionated by SDS-PAGE and
CHO cell PAM proteins were visualized using affinity-
purified antisera to PHM, Exon 16 and CD.
Purification of recombinant Fc-peptide products
Individual Hyperflasks [Corning, Manassas, VA] were
seeded with cells (11 to 45 × 106 cells) from eightconfluent T75 flasks suspended in 565 ml of growth
medium. When the cells were 75-100 % confluent, they
were washed for 30 min with 515 ml CSFM; the wash
medium was discarded and fresh CSFM was added. Spent
medium was harvested after 48 h and replaced with fresh
CSFM; a total of four collections were made over a 7 day
period. Proteins in the spent medium were concentrated
in two steps. The volume was reduced from the 2 l ob-
tained per Hyperflask to about 115 ml using a Vivaflow
200 with a cartridge that had a 30 kDa MWC polyether-
sulfone membrane [05VF20026; VivaScience, Littleton,
MA]; the sample was equilibrated with 20 mM NaHPO4,
pH 7.0 (Binding Buffer) [29]. Ultra-15 Centrifugal Filters
[30,000 MWCO; Millipore, Billerica, MA] equilibrated
with binding buffer were used to reduce the volume to
~2 ml.
Final purification was accomplished using Protein A HP
SpinTrap columns [600 μl; GE Healthcare, Fairfield, CT]
equilibrated with 600 μl Binding Buffer (20 mM sodium
phosphate, pH 7.0). Aliquots of the Centricon concentrate
were allowed to bind sequentially until the entire 2 ml
sample had been added. The column was then washed five
times with 600 μl Binding Buffer. Elution Buffer (400 μl,
0.1 M glycine/HCl, pH 2.7) was allowed to incubate with
the cartridge for 1 min before centrifugation into 30 μl
neutralizing buffer (1 M Tris–HCl, pH 9); this process
was repeated four times. Input and eluates were analyzed
by SDS-PAGE. Purified product concentration was deter-
mined by measuring A280 and using the extinction coeffi-
cient for human Fc.
Mass spectroscopic analysis of purified Fc-peptide products
Initial analysis of Fc-peptide products was carried out by
reversed-phase HPLC/MS of the intact or reduced
(5 mM DTT, 55 °C, 30 min) product on the system de-
scribed below. However, mass accuracy and measurement
precision were insufficient to ensure unambiguous deter-
mination of the state of the peptide carboxy terminus.
Consequently, samples were digested with HRV3C prote-
ase (PreScission, GE Healthcare Bio-Sciences, Pittsburgh,
PA). Digestions of Fc-peptide were performed for 5 h at
5 °C in a buffer consisting of 20 mM TrisHCl, pH 7.0,
150 mM NaCl, 1 mM DTT using one unit of enzyme for
up to 100 μg of protein. Polypeptides resulting from the
digestion were chromatographically resolved on a Waters
(Milford, MA) Acquity UPLC with an Agilent (Santa
Clara, CA) PLRP-S column (2.1 × 50 mm, 5 μ dp, 1000 Å)
using a multi-linear gradient. Buffer A was 0.1 % formic
acid, and buffer B was 0.1 % formic acid in acetonitrile.
The peptides were mass analyzed on a Waters API US
mass spectrometer scanned from m/z 500–3000 at a rate
of 1 Hz. The peptide m/z data was deconvoluted to the
single-charge mass domain by the MaxEnt3 algorithm im-
plemented in the Waters MassLynx data system.
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Fc-peptide products
A cell based homogeneous time-resolved fluorescence
resonance energy transfer competitive immunoassay was
used to quantify bioactive recombinant Fc-fusion pro-
teins. Activation of a Gs or Gi coupled receptor results
in an increase or decrease, respectively, in intracellular
cAMP levels, which were quantified using the LANCE
ultra cAMP assay kit (Perkin Elmer, Waltham, MA). The
Gs-coupled human GLP-1R stably expressed in HEK
cells (in house) was used to quantify GLP-1 related pep-
tides. The Gi-coupled NPY-2R stably expressed in CHO
cells (DiscoveRx, Freemont, CA) was used to quantify
PYY related peptides. In order to detect agonist-induced
reductions in cAMP levels in NPY-2R expressing cells,
they were stimulated with forskolin (3 μM) to increase
the intracellular cAMP.
Assays were performed in 384-well Opti-plates. On
the day of the experiment, vials of frozen cells were
thawed in a 37 °C water bath; cells were transferred into
a tube containing PBS, filtered through a BD Falcon Cell
strainer and counted. Cells were pelleted and suspended
at a concentration of 0.5 × 106 cells/ml in HBSS contain-
ing 5 mM HEPES and 0.1 % BSA. After cells were
allowed to recover at room temperature for at least one
hour, Fc-GLP1 and Fc-PYY fusion proteins were pre-
pared in the same buffer without or with 6 μM foskolin,
respectively; three-fold serial dilutions were made and
cells (10 μl; with 0.5 mM IBMX added after recovery)
and peptide (10 μl) were added to each well. Synthetic
peptides were assayed along with the purified Fc-proteins.
Covered plates were incubated at room temperature with
gentle rotation on a plate shaker (~400 rpm) for 30 min.
LANCE cAMP detection reagent mix (20 μl/well) (Cat#
TRF 0264) was added to each well and allowed to incu-
bate, with shaking, at room temperature for 1 h. Finally,
signal was read on a Perkin Elmer Envision plate reader
using the manufacturer’s recommended protocol.Animal ethics
This work used no animals, only established cell lines.
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